person · Reporting owner
Maggiore Christopher D.
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Zivo Bioscience, Inc.ZIVO · Entity 9611 | Director · 10% owner | January 14, 2026 | January 27, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Zivo Bioscience, Inc.
Report date January 14, 2026 · Filed January 27, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 519,292 |
Reported balance
After 2026-01-14 transaction · row 1
1 source rowRow 1 · 2026-01-14 · Purchase · Acquired 1,766 · Balance 519,292 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 14, 2026 Filed Jan 27, 2026 22:09 UTC | Zivo Bioscience, Inc. ZIVO · Entity 9611 | PurchaseCommon Stock | 1,766 | $8.49 | $14,993.34 |
DisclosureSEC source: 0001654954-26-000631 · section16.xml · nonDerivative · entry 1 Maggiore Christopher D. · CIK 0001436075 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 519,292 Read SEC document |
| October 08, 2025 Filed Oct 9, 2025 20:28 UTC | Zivo Bioscience, Inc. ZIVO · Entity 9611 | PurchaseCommon Stock | 23,682 | $12.01 | $284,420.82 |
DisclosureSEC source: 0001654954-25-011614 · section16.xml · nonDerivative · entry 1 Maggiore Christopher D. · CIK 0001436075 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 517,526 F1 · balance_after: Due to an administrative error, the amount previously reported in this Item 5 overstated the aggregate beneficial ownership of the reporting person by 13,156 shares of Common Stock. The number stated in Item 5 to this Form 4 has been updated to correct the reporting person's aggregate beneficial ownership. Read SEC document |
| October 02, 2025 Filed Oct 7, 2025 00:30 UTC | Zivo Bioscience, Inc. ZIVO · Entity 9611 | GrantNonstatutory Stock Options to buy Common Stock · Derivative | 1,075 | $10.20 Strike: $12.03 | $10,965.00 |
DisclosureSEC source: 0001654954-25-011513 · section16.xml · derivative · entry 1 Maggiore Christopher D. · CIK 0001436075 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,075 Underlying: Common Stock · 1,075 shares Expires 2035-10-02 F1 · price: This option was issued to the reporting person pursuant to the 2024 Equity Incentive Plan for Non-Employee Directors in lieu of retainer fees of $10,964.38 Read SEC document |
| April 08, 2025 Filed Apr 10, 2025 01:42 UTC | Zivo Bioscience, Inc. ZIVO · Entity 9611 | SaleCommon Stock | 20 | $16.25 | $325.00 |
DisclosureSEC source: 0001654954-25-004085 · section16.xml · nonDerivative · entry 1 Maggiore Christopher D. · CIK 0001436075 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 507,000 Read SEC document |
| January 01, 2025 Filed Jan 3, 2025 21:27 UTC | Zivo Bioscience, Inc. ZIVO · Entity 9611 | GrantCommon Stock | 7,277 | $0.00 | $0.00 |
DisclosureSEC source: 0001654954-25-000105 · section16.xml · nonDerivative · entry 2 Maggiore Christopher D. · CIK 0001436075 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 507,020 Read SEC document |
| January 01, 2025 Filed Jan 3, 2025 21:27 UTC | Zivo Bioscience, Inc. ZIVO · Entity 9611 | GrantCommon Stock | 1,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001654954-25-000105 · section16.xml · nonDerivative · entry 1 Maggiore Christopher D. · CIK 0001436075 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 499,743 Read SEC document |
| August 22, 2024 Filed Aug 23, 2024 20:05 UTC | Zivo Bioscience, Inc. ZIVO · Entity 9611 | PurchaseCommon Stock Purchase Warrants · Derivative | 3,133 | $8.34 Strike: $8.34 | $26,129.22 |
DisclosureSEC source: 0001654954-24-011071 · section16.xml · derivative · entry 2 Maggiore Christopher D. · CIK 0001436075 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,133 Underlying: Common Stock · 3,133 shares Expires 2029-08-22 Read SEC document |
| August 22, 2024 Filed Aug 23, 2024 20:05 UTC | Zivo Bioscience, Inc. ZIVO · Entity 9611 | PurchaseCommon Stock | 31,336 | $8.34 | $261,342.24 |
DisclosureSEC source: 0001654954-24-011071 · section16.xml · nonDerivative · entry 1 Maggiore Christopher D. · CIK 0001436075 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 498,443 Read SEC document |
| July 26, 2024 Filed Jul 30, 2024 20:58 UTC | Zivo Bioscience, Inc. ZIVO · Entity 9611 | PurchaseCommon Stock Purchase Warrant · Derivative | 208 | $8.05 Strike: $8.05 | $1,674.40 |
DisclosureSEC source: 0001654954-24-009647 · section16.xml · derivative · entry 2 Maggiore Christopher D. · CIK 0001436075 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 208 Underlying: Common Stock · 208 shares Expires 2029-07-26 Read SEC document |
| July 26, 2024 Filed Jul 30, 2024 20:58 UTC | Zivo Bioscience, Inc. ZIVO · Entity 9611 | PurchaseCommon Stock | 2,080 | $8.05 | $16,744.00 |
DisclosureSEC source: 0001654954-24-009647 · section16.xml · nonDerivative · entry 1 Maggiore Christopher D. · CIK 0001436075 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 467,107 Read SEC document |
| June 12, 2024 Filed Jun 13, 2024 21:37 UTC | Zivo Bioscience, Inc. ZIVO · Entity 9611 | PurchaseCommon Stock | 3,764 | $7.97 | $29,999.08 |
DisclosureSEC source: 0001654954-24-007745 · section16.xml · nonDerivative · entry 2 Maggiore Christopher D. · CIK 0001436075 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 465,027 Read SEC document |
| June 11, 2024 Filed Jun 13, 2024 21:37 UTC | Zivo Bioscience, Inc. ZIVO · Entity 9611 | GrantCommon Stock | 6,273 | $0.00 | $0.00 |
DisclosureSEC source: 0001654954-24-007745 · section16.xml · nonDerivative · entry 1 Maggiore Christopher D. · CIK 0001436075 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 461,263 Read SEC document |
| June 05, 2024 Filed Jun 6, 2024 22:30 UTC | Zivo Bioscience, Inc. ZIVO · Entity 9611 | Disposition to issuerNonstatutory Stock Option to Purchase Common Stock · Derivative | 3,626 | Not disclosed Strike: $16.74 | Not disclosed |
DisclosureSEC source: 0001654954-24-007464 · section16.xml · derivative · entry 7 Maggiore Christopher D. · CIK 0001436075 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,626 shares Expires 2033-06-11 F1 · derivative.exercise_price: The share amount and exercise price have been adjusted from the amount reported on a previous Form 4 to reflect a 1 for 6 reverse stock split of the Issuer's stock in October 2023. F1 · shares: The share amount and exercise price have been adjusted from the amount reported on a previous Form 4 to reflect a 1 for 6 reverse stock split of the Issuer's stock in October 2023. F3 · price: The Issuer canceled options for an aggregate 15,867 shares of the Issuer's common stock granted to the Reporting Person on 10/12/2021, 10/21/2021, 7/28/2022, 12/16/2022, and 6/12/2023. In exchange for the canceled options, the Reporting Person received 36,630 shares of restricted stock. F4 · derivative.exercise_date: The canceled option was issued pursuant to the 2021 Equity Incentive Plan on 6/12/2023 and vests as follows: 25% on the first three 3-month anniversaries of the grant, and 25% on the day prior to the Company's 2024 Annual Meeting of Stockholders, subject to the Reporting Person's continuous service on each applicable vesting date. Read SEC document |
| June 05, 2024 Filed Jun 6, 2024 22:30 UTC | Zivo Bioscience, Inc. ZIVO · Entity 9611 | Disposition to issuerNonstatutory Stock Option to Purchase Common Stock · Derivative | 707 | Not disclosed Strike: $17.16 | Not disclosed |
DisclosureSEC source: 0001654954-24-007464 · section16.xml · derivative · entry 6 Maggiore Christopher D. · CIK 0001436075 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 707 shares Expires 2032-12-15 F1 · shares: The share amount and exercise price have been adjusted from the amount reported on a previous Form 4 to reflect a 1 for 6 reverse stock split of the Issuer's stock in October 2023. F3 · price: The Issuer canceled options for an aggregate 15,867 shares of the Issuer's common stock granted to the Reporting Person on 10/12/2021, 10/21/2021, 7/28/2022, 12/16/2022, and 6/12/2023. In exchange for the canceled options, the Reporting Person received 36,630 shares of restricted stock. F2 · derivative.exercise_date: The canceled options were fully vested. Read SEC document |
| June 05, 2024 Filed Jun 6, 2024 22:30 UTC | Zivo Bioscience, Inc. ZIVO · Entity 9611 | Disposition to issuerNonstatutory Stock Option to Purchase Common Stock · Derivative | 2,632 | Not disclosed Strike: $21.66 | Not disclosed |
DisclosureSEC source: 0001654954-24-007464 · section16.xml · derivative · entry 5 Maggiore Christopher D. · CIK 0001436075 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,632 shares Expires 2032-07-27 F1 · shares: The share amount and exercise price have been adjusted from the amount reported on a previous Form 4 to reflect a 1 for 6 reverse stock split of the Issuer's stock in October 2023. F3 · price: The Issuer canceled options for an aggregate 15,867 shares of the Issuer's common stock granted to the Reporting Person on 10/12/2021, 10/21/2021, 7/28/2022, 12/16/2022, and 6/12/2023. In exchange for the canceled options, the Reporting Person received 36,630 shares of restricted stock. F2 · derivative.exercise_date: The canceled options were fully vested. Read SEC document |
| June 05, 2024 Filed Jun 6, 2024 22:30 UTC | Zivo Bioscience, Inc. ZIVO · Entity 9611 | Disposition to issuerNonstatutory Stock Option to Purchase Common Stock · Derivative | 7,000 | Not disclosed Strike: $33.00 | Not disclosed |
DisclosureSEC source: 0001654954-24-007464 · section16.xml · derivative · entry 4 Maggiore Christopher D. · CIK 0001436075 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,000 shares Expires 2031-10-20 F1 · derivative.exercise_price: The share amount and exercise price have been adjusted from the amount reported on a previous Form 4 to reflect a 1 for 6 reverse stock split of the Issuer's stock in October 2023. F1 · shares: The share amount and exercise price have been adjusted from the amount reported on a previous Form 4 to reflect a 1 for 6 reverse stock split of the Issuer's stock in October 2023. F3 · price: The Issuer canceled options for an aggregate 15,867 shares of the Issuer's common stock granted to the Reporting Person on 10/12/2021, 10/21/2021, 7/28/2022, 12/16/2022, and 6/12/2023. In exchange for the canceled options, the Reporting Person received 36,630 shares of restricted stock. F2 · derivative.exercise_date: The canceled options were fully vested. Read SEC document |
| June 05, 2024 Filed Jun 6, 2024 22:30 UTC | Zivo Bioscience, Inc. ZIVO · Entity 9611 | Disposition to issuerNonstatutory Stock Option to Purchase Common Stock · Derivative | 1,902 | Not disclosed Strike: $26.88 | Not disclosed |
DisclosureSEC source: 0001654954-24-007464 · section16.xml · derivative · entry 3 Maggiore Christopher D. · CIK 0001436075 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,902 shares Expires 2031-10-11 F1 · derivative.exercise_price: The share amount and exercise price have been adjusted from the amount reported on a previous Form 4 to reflect a 1 for 6 reverse stock split of the Issuer's stock in October 2023. F1 · shares: The share amount and exercise price have been adjusted from the amount reported on a previous Form 4 to reflect a 1 for 6 reverse stock split of the Issuer's stock in October 2023. F3 · price: The Issuer canceled options for an aggregate 15,867 shares of the Issuer's common stock granted to the Reporting Person on 10/12/2021, 10/21/2021, 7/28/2022, 12/16/2022, and 6/12/2023. In exchange for the canceled options, the Reporting Person received 36,630 shares of restricted stock. F2 · derivative.exercise_date: The canceled options were fully vested. Read SEC document |
| June 05, 2024 Filed Jun 6, 2024 22:30 UTC | Zivo Bioscience, Inc. ZIVO · Entity 9611 | GrantCommon Stock | 81,544 | $7.96 | $649,090.24 |
DisclosureSEC source: 0001654954-24-007464 · section16.xml · nonDerivative · entry 2 Maggiore Christopher D. · CIK 0001436075 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 454,990 Read SEC document |
| June 05, 2024 Filed Jun 6, 2024 22:30 UTC | Zivo Bioscience, Inc. ZIVO · Entity 9611 | GrantCommon Stock | 36,630 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001654954-24-007464 · section16.xml · nonDerivative · entry 1 Maggiore Christopher D. · CIK 0001436075 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 373,446 F3 · price: The Issuer canceled options for an aggregate 15,867 shares of the Issuer's common stock granted to the Reporting Person on 10/12/2021, 10/21/2021, 7/28/2022, 12/16/2022, and 6/12/2023. In exchange for the canceled options, the Reporting Person received 36,630 shares of restricted stock. Read SEC document |
| December 29, 2023 Filed Jan 2, 2024 21:12 UTC | Zivo Bioscience, Inc. ZIVO · Entity 9611 | PurchaseCommon Stock | 157,692 | $1.30 | $204,999.60 |
DisclosureSEC source: 0001654954-24-000086 · section16.xml · nonDerivative · entry 1 Maggiore Christopher D. · CIK 0001436075 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 336,816 Read SEC document |
| December 13, 2023 Filed Dec 14, 2023 20:45 UTC | Zivo Bioscience, Inc. ZIVO · Entity 9611 | PurchaseCommon Stock | 45,000 | $1.00 | $45,000.00 |
DisclosureSEC source: 0001654954-23-015555 · section16.xml · nonDerivative · entry 1 Maggiore Christopher D. · CIK 0001436075 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 179,124 Read SEC document |
| June 12, 2023 Filed Jun 14, 2023 21:05 UTC | Zivo Bioscience, Inc. ZIVO · Entity 9611 | GrantNonstatutory Stock Option to Purchase Common Stock · Derivative | 21,756 | $0.00 Strike: $2.79 | $0.00 |
DisclosureSEC source: 0001654954-23-008023 · section16.xml · derivative · entry 1 Maggiore Christopher D. · CIK 0001436075 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,756 Underlying: Common Stock · 21,756 shares Expires 2033-06-11 F1 · derivative.exercise_date: The option was issued pursuant to the 2021 Equity Incentive Plan and vests as follows: 25% on the first three 3-month anniversaries of the grant, and 25% on the day prior to the Company's 2024 Annual Meeting of Stockholders, subject to the reporting person's continuous service on each applicable vesting date. Read SEC document |
| December 16, 2022 Filed Dec 20, 2022 21:15 UTC | Zivo Bioscience, Inc. ZIVO · Entity 9611 | GrantNonstatutory Stock Option to Purchase Common Stock · Derivative | 4,244 | $0.00 Strike: $2.86 | $0.00 |
DisclosureSEC source: 0001654954-22-016736 · section16.xml · derivative · entry 1 Maggiore Christopher D. · CIK 0001436075 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,244 Underlying: Common Stock · 4,244 shares Expires 2032-12-15 F1 · derivative.exercise_date: The option was issued pursuant to the 2021 Equity Incentive Plan and vested immediately upon grant. Read SEC document |
| September 14, 2022 Filed Sep 19, 2022 20:16 UTC | Zivo Bioscience, Inc. ZIVO · Entity 9611 | PurchaseCommon Stock | 2,000 | $3.55 | $7,101.40 |
DisclosureSEC source: 0001654954-22-012673 · section16.xml · nonDerivative · entry 2 Maggiore Christopher D. · CIK 0001436075 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 810,305 F2 · price: The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.435 to $3.93 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| September 14, 2022 Filed Sep 19, 2022 20:16 UTC | Zivo Bioscience, Inc. ZIVO · Entity 9611 | PurchaseCommon Stock | 5,200 | $3.53 | $18,346.12 |
DisclosureSEC source: 0001654954-22-012673 · section16.xml · nonDerivative · entry 1 Maggiore Christopher D. · CIK 0001436075 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 808,305 F1 · price: The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.45 to $3.7257 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| September 14, 2022 Filed Feb 14, 2023 13:33 UTC Amendment | Zivo Bioscience, Inc. ZIVO · Entity 9611 | PurchaseCommon Stock | 2,000 | $3.55 | $7,101.40 |
DisclosureSEC source: 0001654954-23-001647 · section16.xml · nonDerivative · entry 2 Maggiore Christopher D. · CIK 0001436075 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 723,282 F2 · price: The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.435 to $3.93 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| September 14, 2022 Filed Feb 14, 2023 13:33 UTC Amendment | Zivo Bioscience, Inc. ZIVO · Entity 9611 | PurchaseCommon Stock | 5,200 | $3.53 | $18,346.12 |
DisclosureSEC source: 0001654954-23-001647 · section16.xml · nonDerivative · entry 1 Maggiore Christopher D. · CIK 0001436075 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 721,282 F1 · price: The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.45 to $3.7257 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F3 · balance_after: The total number of shares reported in Column 5 differs from amounts previously reported, which incorrectly included shares held in the estate of Robert S. McLain and in a related trust, as to which the reporting person was appointed a co-trustee in 2014. Although the reporting person has shared power to vote or to direct the vote, and shared power to dispose or to direct the disposition of, the shares held in the estate and in the trust, the reporting person has no direct or indirect pecuniary interest in such shares. Read SEC document |
| July 28, 2022 Filed Dec 8, 2022 21:17 UTC Amendment | Zivo Bioscience, Inc. ZIVO · Entity 9611 | GrantNonstatutory Stock Option to Purchase Common Stock · Derivative | 15,797 | $0.00 Strike: $3.61 | $0.00 |
DisclosureSEC source: 0001654954-22-016253 · section16.xml · derivative · entry 1 Maggiore Christopher D. · CIK 0001436075 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,797 Underlying: Common stock · 15,797 shares Expires 2022-07-27 F1 · security: This amendment is being filed solely to correct the date of the transaction reported to July 28, 2022. F2 · derivative.exercise_date: The option was issued pursuant to the 2021 Equity Incentive Plan and vests as follows: 25% on the first three 3-month anniversaries of the grant, and 25% on the day prior to the Company's 2023 Annual Meeting of Stockholders, subject to the reporting person's continuous service on each applicable vesting date. Read SEC document |
| July 08, 2022 Filed Aug 1, 2022 20:22 UTC | Zivo Bioscience, Inc. ZIVO · Entity 9611 | GrantNonstatutory Stock Option to Purchase Common Stock · Derivative | 15,797 | $0.00 Strike: $3.61 | $0.00 |
DisclosureSEC source: 0001654954-22-010397 · section16.xml · derivative · entry 1 Maggiore Christopher D. · CIK 0001436075 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,797 Underlying: Common Stock · 15,797 shares Expires 2032-07-27 F1 · derivative.exercise_date: The option was issued pursuant to the 2021 Equity Incentive Plan and vests as follows: 25% on the first three 3-month anniversaries of the grant, and 25% on the day prior to the Company's 2023 Annual Meeting of Stockholders, subject to the reporting person's continuous service on each applicable vesting date. Read SEC document |
| February 11, 2022 Filed Feb 16, 2022 11:02 UTC | Zivo Bioscience, Inc. ZIVO · Entity 9611 | PurchaseCommon Stock | 44,965 | $3.87 | $173,951.60 |
DisclosureSEC source: 0001654954-22-001719 · section16.xml · nonDerivative · entry 3 Maggiore Christopher D. · CIK 0001436075 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 803,105 F3 · price: (3)The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.7199 to $4.07 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| February 10, 2022 Filed Feb 16, 2022 11:02 UTC | Zivo Bioscience, Inc. ZIVO · Entity 9611 | PurchaseCommon Stock | 18,006 | $3.64 | $65,451.81 |
DisclosureSEC source: 0001654954-22-001719 · section16.xml · nonDerivative · entry 2 Maggiore Christopher D. · CIK 0001436075 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 758,140 F2 · price: (2)The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.48 to $3.70 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| February 09, 2022 Filed Feb 16, 2022 11:02 UTC | Zivo Bioscience, Inc. ZIVO · Entity 9611 | PurchaseCommon Stock | 28,363 | $3.55 | $100,694.32 |
DisclosureSEC source: 0001654954-22-001719 · section16.xml · nonDerivative · entry 1 Maggiore Christopher D. · CIK 0001436075 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 740,134 F1 · price: (1)The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.4899 to $3.60 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| January 11, 2022 Filed Jan 14, 2022 22:48 UTC | Zivo Bioscience, Inc. ZIVO · Entity 9611 | PurchaseCommon Stock | 7,560 | $2.64 | $19,956.13 |
DisclosureSEC source: 0001654954-22-000532 · section16.xml · nonDerivative · entry 1 Maggiore Christopher D. · CIK 0001436075 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 711,771 F1 · price: The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.585 to $2.850 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| October 21, 2021 Filed Oct 25, 2021 23:07 UTC | Zivo Bioscience, Inc. ZIVO · Entity 9611 | GrantNonstatutory Stock Option to Purchase Common Stock · Derivative | 42,000 | $0.00 Strike: $5.50 | $0.00 |
DisclosureSEC source: 0001654954-21-011338 · section16.xml · derivative · entry 1 Maggiore Christopher D. · CIK 0001436075 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,000 Underlying: Common Stock · 42,000 shares Expires 2031-10-20 F1 · derivative.exercise_date: The option was issued pursuant to the 2021 Equity Incentive Plan and vests as follows: 25% upon acceptance of the grant, 25% on each of the next two 4-month anniversaries of the grant, and 25% on the day prior to the Company's 2022 Annual Meeting of Stockholders. Read SEC document |
| October 12, 2021 Filed Oct 16, 2021 01:17 UTC | Zivo Bioscience, Inc. ZIVO · Entity 9611 | GrantNonstatutory Stock Option to Purchase Common Stock · Derivative | 11,416 | $0.00 Strike: $4.48 | $0.00 |
DisclosureSEC source: 0001654954-21-011167 · section16.xml · derivative · entry 1 Maggiore Christopher D. · CIK 0001436075 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,416 Underlying: Common Stock · 11,416 shares Expires 2031-10-11 F1 · derivative.exercise_date: The option was issued pursuant to the 2021 Equity Incentive Plan and vests as follows: 25% on the first three 3-month anniversaries of the grant, and 25% on the day prior to the Company's 2022 Annual General Meeting of Stockholders, subject to the reporting person's continuous service on each applicable vesting date. Read SEC document |
| June 02, 2021 Filed Jun 4, 2021 19:44 UTC | Zivo Bioscience, Inc. ZIVO · Entity 9611 | PurchaseCommon Stock Purchase Warrant · Derivative | 100,000 | $0.01 Strike: $5.50 | $1,000.00 |
DisclosureSEC source: 0001078782-21-000534 · primary_doc.xml · derivative · entry 2 Maggiore Christopher D. · CIK 0001436075 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2026-06-02 Read SEC document |
| June 02, 2021 Filed Jun 4, 2021 19:44 UTC | Zivo Bioscience, Inc. ZIVO · Entity 9611 | PurchaseCommon Stock | 100,000 | $4.99 | $499,000.00 |
DisclosureSEC source: 0001078782-21-000534 · primary_doc.xml · nonDerivative · entry 1 Maggiore Christopher D. · CIK 0001436075 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 704,211 F1 · balance_after: The share amount has been adjusted to reflect the reverse stock split effective on May 28, 2021 whereby each eighty shares of common stock issued and outstanding prior to the split were combined and converted into one share of common stock. Read SEC document |
| September 30, 2020 Filed Dec 2, 2020 00:36 UTC | Zivo Bioscience, Inc. ZIVO · Entity 9611 | Tax withholdingCommon Stock Purchase Warrant · Derivative | 500,000 | Not disclosed Strike: $0.12 | Not disclosed |
DisclosureSEC source: 0001078782-20-000935 · primary_doc.xml · derivative · entry 4 Maggiore Christopher D. · CIK 0001436075 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2025-09-30 F1 · price: The warrants were issued to the reporting person as compensation for acting as a director. Read SEC document |
| September 09, 2020 Filed Dec 2, 2020 00:36 UTC | Zivo Bioscience, Inc. ZIVO · Entity 9611 | Exercise / conversionCommon Stock Purchase Warrant · Derivative | 250,000 | $0.00 Strike: $0.10 | $0.00 |
DisclosureSEC source: 0001078782-20-000935 · primary_doc.xml · derivative · entry 3 Maggiore Christopher D. · CIK 0001436075 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2020-09-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 09, 2020 Filed Dec 2, 2020 00:36 UTC | Zivo Bioscience, Inc. ZIVO · Entity 9611 | Tax withholdingCommon Stock | 46,296 | $0.11 | $5,092.56 |
DisclosureSEC source: 0001078782-20-000935 · primary_doc.xml · nonDerivative · entry 2 Maggiore Christopher D. · CIK 0001436075 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,907,826 Read SEC document |
| September 09, 2020 Filed Dec 2, 2020 00:36 UTC | Zivo Bioscience, Inc. ZIVO · Entity 9611 | Exercise / conversionCommon Stock | 250,000 | $0.10 | $25,000.00 |
DisclosureSEC source: 0001078782-20-000935 · primary_doc.xml · nonDerivative · entry 1 Maggiore Christopher D. · CIK 0001436075 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,954,122 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 22, 2020 Filed Feb 11, 2020 17:50 UTC | Zivo Bioscience, Inc. ZIVO · Entity 9611 | PurchaseCommon Stock | 24,000 | $0.15 | $3,600.00 |
DisclosureSEC source: 0001078782-20-000094 · primary_doc.xml · nonDerivative · entry 4 Maggiore Christopher D. · CIK 0001436075 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,704,122 Read SEC document |
| January 16, 2020 Filed Feb 11, 2020 17:50 UTC | Zivo Bioscience, Inc. ZIVO · Entity 9611 | PurchaseCommon Stock | 20,000 | $0.16 | $3,200.00 |
DisclosureSEC source: 0001078782-20-000094 · primary_doc.xml · nonDerivative · entry 3 Maggiore Christopher D. · CIK 0001436075 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,680,122 Read SEC document |
| January 15, 2020 Filed Feb 11, 2020 17:50 UTC | Zivo Bioscience, Inc. ZIVO · Entity 9611 | PurchaseCommon Stock | 16,000 | $0.16 | $2,560.00 |
DisclosureSEC source: 0001078782-20-000094 · primary_doc.xml · nonDerivative · entry 2 Maggiore Christopher D. · CIK 0001436075 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,660,122 Read SEC document |
| January 10, 2020 Filed Feb 11, 2020 17:50 UTC | Zivo Bioscience, Inc. ZIVO · Entity 9611 | PurchaseCommon Stock | 5,000 | $0.16 | $800.00 |
DisclosureSEC source: 0001078782-20-000094 · primary_doc.xml · nonDerivative · entry 1 Maggiore Christopher D. · CIK 0001436075 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,644,122 Read SEC document |
| January 03, 2020 Filed Jan 7, 2020 19:04 UTC | Zivo Bioscience, Inc. ZIVO · Entity 9611 | PurchaseCommon Stock | 5,000 | $0.16 | $800.00 |
DisclosureSEC source: 0001078782-20-000005 · primary_doc.xml · nonDerivative · entry 6 Maggiore Christopher D. · CIK 0001436075 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,639,122 Read SEC document |
| December 30, 2019 Filed Jan 7, 2020 19:04 UTC | Zivo Bioscience, Inc. ZIVO · Entity 9611 | PurchaseCommon Stock | 50,000 | $0.16 | $8,000.00 |
DisclosureSEC source: 0001078782-20-000005 · primary_doc.xml · nonDerivative · entry 5 Maggiore Christopher D. · CIK 0001436075 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,634,122 Read SEC document |
| December 26, 2019 Filed Jan 7, 2020 19:04 UTC | Zivo Bioscience, Inc. ZIVO · Entity 9611 | PurchaseCommon Stock | 65,000 | $0.16 | $10,400.00 |
DisclosureSEC source: 0001078782-20-000005 · primary_doc.xml · nonDerivative · entry 4 Maggiore Christopher D. · CIK 0001436075 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,584,122 Read SEC document |
| December 24, 2019 Filed Jan 7, 2020 19:04 UTC | Zivo Bioscience, Inc. ZIVO · Entity 9611 | PurchaseCommon Stock | 50,000 | $0.16 | $8,000.00 |
DisclosureSEC source: 0001078782-20-000005 · primary_doc.xml · nonDerivative · entry 3 Maggiore Christopher D. · CIK 0001436075 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,519,122 Read SEC document |
| December 23, 2019 Filed Jan 7, 2020 19:04 UTC | Zivo Bioscience, Inc. ZIVO · Entity 9611 | PurchaseCommon Stock | 225,125 | $0.14 | $31,517.50 |
DisclosureSEC source: 0001078782-20-000005 · primary_doc.xml · nonDerivative · entry 2 Maggiore Christopher D. · CIK 0001436075 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,469,122 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.